Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum

Cytotherapy

Volumn 14, Issue 5, 2012, Pages 570-583

  Bieback, Karen ^a   Hecker, Andrea ^a   Schlechter, Tanja ^a   Hofmann, Ilse ^a   Brousos, Nikos ^b   Redmer, Torben ^c   Besser, Daniel ^c   Klter, Harald ^a   Mller, Albrecht M ^b   Becker, Matthias ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Max Delbrck Center   (Germany)

Author keywords

Adipose tissue derived mesenchymal stromal cells; Fetal bovine serum; Human serum; Long term culture; Potency; Replicative aging; Safety

Indexed keywords

BOVINE SERUM ALBUMIN; GROWTH FACTOR; HUMAN SERUM ALBUMIN;

ADIPOSE TISSUE; ARTICLE; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LONG TERM EXPOSURE; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 84859777676     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.652809     Document Type: Article

References (50)

1. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2:313-9.
2. Tolar J, Le Blanc K, Keating A, Blazar BR. Concise review. Hitting the right spot with mesenchymal stromal cells. Stem Cells. 2010;28:1446-55.
3. Levi B, Longaker MT. Adipose derived stromal cells for skeletal regenerative medicine. Stem Cells. 2011;29:576-82.
4. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramirez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582-91.
5. Madonna R, De Caterina R. Adipose tissue: a new source for cardiovascular repair. J Cardiovasc Med (Hagerstown). 2010;11:71-80.
6. Garcia-Olmo D, Herreros D, Pascual M, Pascual I, De-La- Quintana P, Trebol J, et al. Treatment of enterocutaneous fi stula in Crohn ' s disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis. 2009;24:27-30.
7. Mannello F, Tonti GA. Concise review. No breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells. 2007;25:1603-9.
8. Honn KV, Singley JA, Chavin W. Fetal bovine serum: a multivariate standard. Proc Soc Exp Biol Med. 1975;149:344-7.
9. Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells. 2007;25:197-202.
10. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica. 2007;92:1208-15.
11. Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007;47:1436-46.
12. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, et al. Good manufacturing practice production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007;47:520-8.
13. Bieback K, Ha VA, Hecker A, Grassl M, Kinzebach S, Solz H, et al. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A. 2010;16:3467-84.
14. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009;27:2331-41.
15. Kocaoemer A, Kern S, Kluter H, Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells. 2007;25:1270-8.
16. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005;205:228-36.
17. Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell. 2011;8:618-28.
18. Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M. Controversial issue: is it safe to employ mesenchymal stem cells in cell-based therapies? Exp Gerontol. 2008;43:1018-23.
19. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, et al. Defi ning the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12:576-8.
20. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, et al. Human bone marrow derived mesen chymal stem cells do not undergo transformation after longterm in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142-9.
21. Rubin H. Multistage carcinogenesis in cell culture. Dev Biol (Basel). 2001;106:61-6; discussion 7, 143-60.
22. Vukicevic V, Jauch A, Dinger TC, Gebauer L, Hornich V, Bornstein SR, et al. Genetic instability and diminished differentiation capacity in long-term cultured mouse neurosphere cells. Mech Ageing Dev. 2010;131:124-32.
23. Wieser M, Stadler G, Bohm E, Borth N, Katinger H, Grillari J, et al. Nuclear fl ow FISH: isolation of cell nuclei improves the determination of telomere lengths. Exp Gerontol. 2006;41:230-5.
24. Breuninger S, Reidenbach S, Sauer CG, Strobel P, Pfi tzenmaier J, Trojan L, et al. Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. Am J Pathol. 2010;176:2509-19.
25. Wuchter P, Boda-Heggemann J, Straub BK, Grund C, Kuhn C, Krause U, et al. Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cells. Cell Tissue Res. 2007;328:499-514.
26. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defi ning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
27. Rojewski MT, Weber BM, Schrezenmeier H. Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemoth. 2008;35:168-84.
28. Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cellassociated markers. Stem Cells. 2006;24:376-85.
29. Mutin M, Dignat-George F, Sampol J. Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens. 1997;50:449-58.
30. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509-25.
31. Najar M, Raicevic G, Boufker HI, Fayyad-Kazan H, De Bruyn C, Meuleman N, et al. Adipose-tissue-derived and Wharton ' s jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A. 2010;16:3537-46.
32. EMEA. Guideline on Human Cell-Based Medicinal Products. Offi cial guideline of the European Medicines Agency: EMA, London, Great Britain, 2008 (Doc. Ref. EMEA/ CHMP/410869/2006)
33. C holewa D, Stiehl T, Schellenberg A, Bokermann G, Joussen S, Koch C, et al. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant. 2011;20:1409-22.
34. Fujimoto A, Nakagawa H, Hosono N, Nakano K, Abe T, Boroevich KA, et al. Whole-genome sequencing and comprehensive variant analysis of a Japanese individual using massively parallel sequencing. Nat Genet. 2010;42:931-6.
35. Peacocke M, Campisi J. Cellular senescence: a refl ection of normal growth control, differentiation, or aging? J Cell Biochem. 1991;45:147-55.
36. Lee JS, Lee MO, Moon BH, Shim SH, Fornace AJ Jr, Cha HJ. Senescent growth arrest in mesenchymal stem cells is bypassed by Wip1-mediated downregulation of intrinsic stress signaling pathways. Stem Cells. 2009;27:1963-75.
37. Heo JY, Jing K, Song KS, Seo KS, Park JH, Kim JS, et al. Downregulation of APE1/Ref-1 is involved in the senescence of mesenchymal stem cells. Stem Cells. 2009;27:1455-62.
38. Molchadsky A, Shats I, Goldfi nger N, Pevsner-Fischer M, Olson M, Rinon A, et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One. 2008;3:e3707.
39. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem. 2002;277:29792-802.
40. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood. 2010;115:1549-53.
41. Dahl JA, Duggal S, Coulston N, Millar D, Melki J, Shahdadfar A, et al. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol. 2008;52:1033-42.
42. Schellenberg A, Lin Q, Schuler H, Koch CM, Joussen S, Denecke B, et al. Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging (Albany NY). 2011; 3:873-88.
43. Charbord P. Hemopoietic stem cells: analysis of some parameters critical for engraftment. Stem Cells. 1994;12:545-62.
44. Rada T, Santos TC, Marques AP, Correlo VM, Frias AM, Castro AG, et al. Osteogenic differentiation of two distinct subpopulations of human adipose-derived stem cells: an in vitro and in vivo study. J Tissue Eng Regen Med. 2012;6:1-11.
45. Lin CS, Xin ZC, Deng CH, Ning H, Lin G, Lue TF. Defi ning adipose tissue-derived stem cells in tissue and in culture. Histol Histopathol. 2010;25:807-15.
46. Wagner W, Ho AD, Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B-Re. 2010;16:445-53.
47. Duggal S, Brinchmann JE. Importance of serum source for the in vitro replicative senescence of human bone marrow derived mesenchymal stem cells. J Cell Physiol. 2011;226:2908-15.
48. Lee WC, Rubin JP, Marra KG. Regulation of alpha-smooth muscle actin protein expression in adipose-derived stem cells. Cells Tissues Organs. 2006;183:80-6.
49. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem. 1998;31:205-62.
50. Suga H, Matsumoto D, Eto H, Inoue K, Aoi N, Kato H, et al. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells Dev. 2009; 18:1201-10.